

EURETINA 2026 Preview – Clinical and AI / ML



LucidQuest Intelligence
Accelerate your success

EURETINA 2026

2026

1



EURETINA 2026 Preview – Table of Contents

• <u>New Trends in Retina Treatment Strategy At EURETINA'26</u>	<u>3-5</u>
• <u>Key Sessions To Watch</u>	<u>6</u>
• <u>Industry-sponsored Sessions & Focus Areas At EURETINA 2026</u>	<u>7-14</u>
• <u>Competitive Landscape At a Glance at EURETINA 2026</u>	<u>8-9</u>
• <u>Key Industry-sponsored Sessions At EURETINA 2026</u>	<u>10-14</u>
• <u>New Entrants</u>	<u>15</u>
• <u>AI/ML Trends & Strategic Watchpoints At EURETINA 2026</u>	<u>16-18</u>
• <u>AI / Digital Health Angle At EURETINA 2026</u>	<u>17-18</u>
• <u>What We're Watching For Post-congress</u>	<u>19</u>
• <u>Get In Touch With LucidQuest</u>	<u>20</u>



- **nAMD differentiation is increasingly moving toward durability and treatment burden**

- EURETINA 2026 will bring together data on longer-acting and sustained-delivery approaches, including EYP-1901, aflibercept 8 mg, faricimab and other long-acting strategies. Sessions will examine extended dosing, real-world treatment burden and the practical impact of reducing injection frequency. The competitive question will be whether newer approaches can combine durability with sustained anatomical and functional control



- **Gene therapy is moving across multiple retinal indications**

- Gene and genetic medicine approaches will feature across nAMD, DME and inherited retinal disease, including 4D-150, Ixo-vec, laruzova and emerging gene-therapy platforms. The programme will include longer-term follow-up as well as earlier-stage clinical development, bringing durability, delivery and potential treatment burden reduction into the discussion





- **GA treatment strategies are expanding beyond a single biological pathway**

- EURETINA 2026 will feature multiple approaches to geographic atrophy, including complement-targeted therapies such as APL-3007 and vonaprumment alongside vision-restoration, neuroprotective, regenerative and device-based approaches. PRIMA 36-month outcomes, emerging neuroprotective strategies and regenerative medicine sessions will broaden the discussion around slowing disease progression versus restoring visual function



- **Precision phenotyping is becoming increasingly important in retinal treatment**

- Sessions will examine structural biomarkers, multimodal imaging, aqueous biomarkers and AI-supported phenotyping across AMD and diabetic retinal disease. The programme will increasingly connect imaging and biological characteristics with disease progression, patient selection, treatment response and personalised management, potentially moving retinal care beyond a one-size-fits-all treatment approach



• **AI is moving from retinal image analysis toward clinical decision support**

- EURETINA 2026 will feature AI across screening, diagnosis, risk prediction, biomarker analysis and treatment decision-making, including AI for DR screening, OCTA analysis, nAMD management and AI-derived retinal biomarkers. Dedicated sessions on Gen AI and AI implementation will examine how these technologies could move from image interpretation toward supporting real-world clinical workflows



• **Retinal innovation is increasingly focused on changing how therapies are delivered**

- Beyond new molecules, the programme will feature intravitreal inserts, reservoirs, gene-therapy delivery, retinal implants, bioelectric stimulation and other device-enabled approaches. EYP-1901, PRIMA, MgShell, i-Lumen and emerging gene-therapy platforms illustrate a broader shift toward addressing delivery frequency, treatment burden, functional restoration and practical implementation alongside conventional pharmacological efficacy





Key Sessions To Watch

Date	Session Title (short)	Type	Author / Institution	Why Watch
02 Oct 2026	4D-150: 2-Year PRISM Phase 2b Results	EURETINA Session	Frank Holz	Provides longer-term clinical follow-up for intravitreal gene therapy in a broad nAMD population and links into Phase 3 development
02 Oct 2026	PRIMAvera: 36-Month Outcomes	EURETINA Session	Mahi Muqit	Provides extended visual-restoration data for the PRIMA subretinal neurostimulation system in GA
02 Oct 2026	EYP-1901: LUGANO Phase 3 Results	EURETINA Session	Roger Goldberg	Key readout covering efficacy, treatment burden and safety for a sustained-release approach in wet AMD
02 Oct 2026	Ixo-vec: LUNA 2-Year Results	Free Paper	Mark Barakat	Extends the clinical evidence base for intravitreal gene therapy in nAMD
02 Oct 2026	APL-3007 Phase 1 Results	Free Paper	Dilsher S. Dhoot	Provides early clinical data for a systemic C3 siRNA approach in GA
02 Oct 2026	Tarcocimab Tedromer: GLOW2	Free Paper	Margaret Chang	Showcase Phase 3 primary-endpoint results in diabetic retinopathy
02 Oct 2026	OLN324 vs Faricimab - JADE	Free Paper	David Eichenbaum	Provides a direct clinical comparison of a VEGF/Ang2 bispecific approach with faricimab in DME/nAMD
04 Oct 2026	Tinlarebant: Phase 3 DRAGON	Free Paper	Michel Michaelides	Provides topline Phase 3 data in adolescent Stargardt disease

Industry-Sponsored Sessions & Focus Areas – EURETINA 2026





EURETINA 2026– Competitive Landscape at a Glance (1/2)

Name	Sessions	Companies / Assets	Why It Matters
Durability & sustained delivery in nAMD	Multiple	EyePoint / EYP-1901; Roche / faricimab; Bayer / aflibercept 8 mg; 4DMT / 4D-150	EURETINA 2026 will test whether longer-acting and sustained-delivery approaches can differentiate through reduced treatment burden while maintaining durable disease control
Gene therapy in nAMD & DME	Multiple	4DMT / 4D-150; Adverum / Ixo-vec; EyePoint / EYP-1901	The congress will provide a broader view of whether gene therapy can move retinal treatment toward longer-lasting disease control and reduce reliance on repeated injections
GA: Complement-targeted approaches	Multiple	APL-3007; vonaprument; complement-directed approaches	EURETINA 2026 will examine whether different complement-targeted strategies can translate biological pathway modulation into meaningful disease modification
GA: Vision restoration & regenerative approaches	Multiple	Science Corporation / PRIMA; Astellas / regenerative medicine; emerging cell & gene therapies	The focus will extend beyond slowing GA progression toward whether emerging approaches can preserve or restore visual function in advanced disease



EURETINA 2026– Competitive Landscape at a Glance (2/2)

Name	Sessions	Companies / Assets	Why It Matters
DME treatment optimisation & differentiation	Multiple	Roche / faricimab; Bayer / aflibercept 8 mg; AbbVie / emerging DME approaches; 4DMT / 4D-150	EURETINA 2026 will broaden the DME discussion from efficacy alone to durability, fluid control, inflammatory phenotypes and treatment selection across different patient profiles
AI-enabled retinal diagnosis & monitoring	Multiple	Heidelberg Engineering; ZEISS; Optos; RetInSight; Bayer; AbbVie	The congress will test whether AI can move beyond image analysis toward clinically useful phenotyping, biomarker identification, risk prediction and treatment decision support
Next-generation retinal imaging	Multiple	ZEISS; Heidelberg Engineering; Optos; TowardPi; Optopol	EURETINA 2026 will explore whether higher-resolution, multimodal and ultra-widefield imaging can provide additional information for diagnosis, monitoring and treatment planning
Biosimilars & real-world retinal care	Multiple	Amgen; ophthalmic biosimilar approaches	The focus will shift toward whether regulatory, clinical and real-world evidence can support greater confidence in biosimilar use and inform treatment decisions in routine retinal care



Key Industry-Sponsored Sessions at EURETINA 2026 (1/5)



• Roche:

- Focus Areas: Faricimab, nAMD, DME & Continuous Drug Delivery
- The programme is set to examine continuous drug delivery in nAMD, alongside real-world evidence on faricimab and its broader clinical and system-level value. Discussion is expected to centre on durability, treatment burden and the practical implications of longer-acting retinal care



• Bayer:

- Focus Areas: Aflibercept 8 mg, RWE & AI-Guided Retinal Care
- Bayer's sessions are expected to address aflibercept 8 mg across different patient profiles, alongside real-world evidence and AI-guided decision-making. The focus is on translating treatment and RWE data into more streamlined retinal care



Key Industry-Sponsored Sessions at EURETINA 2026 (2/5)



- **AbbVie:**

- Focus Areas: DME, AI & Precision Treatment
- AbbVie's DME programme is set to explore AI-supported phenotyping, inflammatory disease profiles and earlier treatment decisions. The discussion is expected to highlight how greater understanding of patient heterogeneity could support more tailored DME management



- **Astellas:**

- Focus Areas: Geographic Atrophy & Long-Term Management
- The session is set to address geographic atrophy through EZ attenuation, long-term clinical management and real-world cases. Discussion is expected to focus on how clinicians may approach GA assessment and management over the longer term



Key Industry-Sponsored Sessions at EURETINA 2026 (3/5)

- **4D Molecular Therapeutics:**

- Focus Areas: 4D-150, Gene Therapy, nAMD & DME
- The programme is set to present clinical evidence for 4D-150 across nAMD and DME, including PRISM, 4FRONT and SPECTRA data. The discussion is expected to highlight the potential role of intravitreal gene therapy in reducing the burden of repeated retinal treatment

- **MSD:**

- Focus Areas: Wnt, TIE2 & Retinal Vascular Disease
- MSD's programme is expected to examine emerging mechanisms in retinal vascular disease, including Wnt activation and direct TIE2 activation. AMARONE and RIOJA data are set to provide insight into approaches targeting vascular stability and the blood-retina barrier



Key Industry-Sponsored Sessions at EURETINA 2026 (4/5)



- **Alcon:**

- Focus Areas: **Vitreoretinal Surgery & Dry AMD**
- Alcon's programme is set to cover surgical innovation through clinical cases and practical discussion in vitreoretinal surgery. A separate session is expected to examine Valeda photobiomodulation and its clinical and anatomical findings in dry AMD



- **Amgen:**

- Focus Areas: **Biosimilars & Real-World Evidence**
- Amgen's session is set to examine the regulatory, clinical and real-world evidence supporting ophthalmic biosimilars. Discussion will focus on how the evolving evidence base may inform clinical decision-making and adoption in retinal care



Key Industry-Sponsored Sessions at EURETINA 2026 (5/5)



• **Optos:**

- Focus Areas: **Ultra-Widefield Imaging & Peripheral Retina**
- Optos' programme is expected to demonstrate how ultra-widefield imaging can extend retinal assessment beyond the macula, including peripheral nonperfusion in diabetic retinopathy. Additional discussion will address widefield OCT and applications across AMD and other retinal conditions



• **Heidelberg Engineering:**

- Focus Areas: **High-Resolution OCT & AI Biomarkers**
- Heidelberg Engineering is set to showcase ultra-high axial-resolution OCT clinical cases alongside a debate on AI-derived retinal biomarkers. The session is expected to examine the potential clinical value of higher-resolution imaging and AI-supported biomarker interpretation





New Entrants

Asset / Company	2026 Presence
Vonaprument	Baseline Characteristics of Participants in ARCHER II: A Phase 3 Study of Vision Protection of Vonaprument, a C1q inhibitor, in Dry AMD with GA
Sonpiretigene Isteparvovec	Vision Improvement in Macular Degeneration with Sonpiretigene Isteparvovec Optogenetic Therapy: First Direct-to-Phase 2 Randomized, Controlled Trial
APL-3007	Phase 1 Results of APL-3007: A Novel Systemic C3 siRNA for Geographic Atrophy Secondary to AMD
PST-611-CT1	Transferrin in geographic atrophy patients using non-viral ocular gene therapy: safety, tolerability and early efficacy results from PST-611-CT1, a first-in-human trial
Sura-vec	Subretinal delivery of investigational sura-vec gene therapy for neovascular age-related macular degeneration: Long-term follow-up of phase 1/2a participants
SAR402663	A Phase 1/2 Study of Single-Dose Intravitreal SAR402663, an AAV Gene Therapy Expressing sFLT01, in Participants with Neovascular Age-related Macular Degeneration
LX102	Subretinal LX102 gene therapy for neovascular age-related macular degeneration: 1-year results of a randomized, active-controlled phase 2 trial
TTX-381	Two Year Results of the Phase 1/2 TTX-381 gene therapy clinical trial for CLN2 Batten disease-related retinopathy





AI / Digital Health Angle at EURETINA 2026 (1/2)

- **AI is moving from retinal image analysis toward clinical decision support**

- EURETINA 2026 is set to expand the AI discussion beyond image interpretation toward clinical decision-making, disease monitoring and treatment optimisation. Sessions will cover AI in retinal disease, AI-supported biomarkers, clinical care, drug development and patient-centred management, suggesting a broader move toward integrating AI into retinal workflows

- **AI-enabled prediction and monitoring are becoming increasingly relevant across retinal diseases**

- The programme will examine AI applications across AMD, geographic atrophy, diabetic retinopathy and other retinal diseases, including prediction of disease progression, risk assessment and monitoring. The key question is whether these approaches can provide clinically actionable information rather than simply improve diagnostic accuracy

- **Generative AI and large language models are entering retinal practice**

- Dedicated sessions on large language models and AI-based LLM integration in vitreoretinal surgery indicate that generative AI is moving into clinical and surgical workflows. Discussion is expected to address how these tools could support clinical reasoning, decision-making and access to retinal knowledge while retaining clinician oversight



AI / Digital Health Angle at EURETINA 2026 (2/2)

- **Key sessions include:**

- From Data to Insights: Harnessing the Power of AI to Transform Drug Development and Clinical Care
- Modern imaging and AI in diabetic retinopathy: biomarkers to bedside
- Integrating Artificial Intelligence-based Large Language Models in Vitreoretinal Surgery
- AI in Clinical Practice: A Practical Patient-Centered Roadmap for Geographic Atrophy Management
- Oculomics and Artificial Intelligence in Retinal Diseases: The Retina as a Window to Systemic Health

- **Sessions suggest AI and digital tools are increasingly being used to improve:**

- Disease progression prediction across AMD and other retinal diseases
- AI-supported retinal imaging and biomarker identification
- Diabetic retinopathy screening and risk prediction
- Geographic atrophy monitoring and patient management
- Clinical decision-making and treatment planning
- Vitreoretinal surgical planning and workflow support
- Drug development and clinical-trial applications
- Integration of large language models into retinal practice



What We're Watching for Post-EURETINA 2026

- Whether **durability and reduced treatment burden** become increasingly important dimensions of differentiation **in nAMD**, alongside efficacy and safety.
- Whether **emerging GA approaches** broaden the **treatment paradigm** beyond complement inhibition, particularly **through vision restoration, cell-based, neuroprotective and device-based approaches**.
- Whether **gene therapies** demonstrate sufficient **durability and clinical consistency** to support broader development across **nAMD, DME** and inherited retinal disease.
- Whether **precision imaging and AI-derived phenotyping** translate into more differentiated **DME and GA treatment** decisions.
- Whether **AI moves from proof-of-concept and analytical validation toward routine clinical implementation**, particularly in screening, risk stratification and treatment monitoring.
- Whether **emerging mechanisms such as Wnt and TIE2** generate further interest in **retinal vascular disease** beyond established VEGF-focused strategies.
- Whether **real-world evidence increasingly influences treatment selection and adoption, particularly for durable therapies**, aflibercept 8 mg, faricimab and biosimilars.
- Whether **functional vision restoration becomes a more established development direction in GA**, as longer-term PRIMA data and other emerging approaches mature

Strategic Insights and Strategy Development is our focus



COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM